ukwelapha umdlavuza wamaphaphu okungewona amancane

Umdlavuza wamaphaphu ongewona omncane (NSCLC) wuhlobo oluvamile lomdlavuza wamaphaphu. Izinketho zokwelapha ze-NSCLC ziyahlukahluka futhi zincike ezintweni ezimbalwa, okuhlanganisa isigaba somdlavuza, impilo yesiguli iyonke, kanye nokuguqulwa kofuzo okuthile ngaphakathi kwesimila. Lo mhlahlandlela unikeza umbono wezindlela zokwelapha eziyinhloko ze-NSCLC, kusukela ekuhlinzweni nasekwelapheni ngemisebe kuya ekwelapheni okuhlosiwe kanye nokwelashwa kwamasosha omzimba, ukunika amandla iziguli kanye nabanakekeli ngolwazi lokwenza izinqumo ezinolwazi.Umdlavuza wamaphaphu ongewona omncane (NSCLC) iyiqembu lomdlavuza wamaphaphu eliziphatha ngendlela efanayo. Izinhlobo eziyinhloko ze-NSCLC zifaka i-adenocarcinoma, i-squamous cell carcinoma, kanye ne-cell carcinoma enkulu. Ukuxilongwa okunembile, okubandakanya ukuhlolwa kwesiteji kanye nokuhlolwa kwamangqamuzana, kubalulekile ekunqumeni isu lokwelapha eliphumelela kakhulu. I-Shandong Baofa Cancer Research Institute izinikele ocwaningweni lomdlavuza kanye nokuthuthukiswa kwezindlela ezintsha zokwelapha, funda kabanzi ku https://baofahospital.com.Isiteji se-NSCLCNSCLC sihlelwa kusetshenziswa uhlelo lwe-TNM (I-Tumor, Node, Metastasis). Isiteji sichaza ubukhulu nendawo yesimila esiyinhloko (T), noma ngabe umdlavuza ususabalele kuma-lymph nodes aseduze (N), kanye nokuthi umdlavuza usuqhamuke yini ezindaweni ezikude (M). Izigaba zisukela ku-I (isigaba sangaphambi kwesikhathi) kuye ku-IV (isigaba esithuthukisiwe).Ukuhlolwa Kwemolekyuli Kwe-NSCLCUkuhlolwa kwe-molecular kukhomba ukuguqulwa kwezakhi zofuzo ezithile noma ukungahambi kahle kwamaprotheni ngaphakathi kwamaseli wesimila. Lawa ma-biomarker angasiza ekunqumeni ukuthi isiguli siyikhandidethi lokwelapha okuhlosiwe. Izinguquko ezivamile zihlanganisa i-EGFR, ALK, ROS1, BRAF, nezinye. Imiphumela yokuhlolwa kwamangqamuzana ithinta kakhulu izinqumo zokwelashwa.Okuvamile Ukwelashwa kwe-NSCLCUkuhlinzwaUkuhlinzwa kuvame ukuba wumugqa wokuqala wokwelapha we-NSCLC yesigaba sokuqala (izigaba I kanye nesesi-II). Umgomo uwukukhipha isimila nanoma yimaphi ama-lymph nodes aseduze. Izinhlobo zokuhlinza zihlanganisa: Ukususwa Kwe-Wedge: Ukususwa kwesiqephu sephaphu esincane, esimise okwe-wedge. I-Segmentectomy: Ukususwa kwengxenye enkulu yephaphu kunokukhishwa koweji. I-Lobectomy: Ukususwa kwe-lobe yonke yephaphu. Lena inqubo yokuhlinzwa evame kakhulu ye-NSCLC. I-Pneumonectomy: Ukususwa kwephaphu lonke. Lokhu akuvamile futhi kugcinelwe izimila ezibanzi kakhulu.Ukwelashwa ngemisebeUkwelashwa ngeRadiation kusebenzisa imisebe enamandla amakhulu ukubulala amangqamuzana omdlavuza. Ingasetshenziswa njengokwelashwa okuyinhloko, ngemva kokuhlinzwa ukubulala noma imaphi amangqamuzana omdlavuza asele, noma ukukhulula izimpawu (i-palliative radiation). Izinhlobo ezahlukene ze-radiation therapy zihlanganisa: I-Beam Radiation Therapy yangaphandle (EBRT): Imisebe ihanjiswa emshinini ongaphandle komzimba. I-Stereotactic Body Radiation Therapy (SBRT): Iletha imithamo ephezulu yemisebe endaweni encane, eqondiswe kahle. Ivamise ukusetshenziselwa i-NSCLC yesigaba sokuqala lapho ukuhlinzwa kungeyona inketho. I-Brachytherapy (I-Internal Radiation Therapy): I-radioactive material ifakwa ngqo ngaphakathi kwesimila noma eduze naso.I-ChemotherapyI-Chemotherapy isebenzisa imithi ukuze ibulale amangqamuzana omdlavuza kuwo wonke umzimba. Ivamise ukusetshenziswa ekuhlanganisweni nokuhlinzwa noma ukwelashwa ngemisebe, noma njengokwelashwa okuyinhloko kwabathuthukisiwe I-NSCLC. Imithi ejwayelekile ye-chemotherapy ye-NSCLC ihlanganisa i-cisplatin, i-carboplatin, i-paclitaxel, i-docetaxel, i-pemetrexed, ne-gemcitabine.I-Targeted Therapy for Ukwelashwa kwe-NSCLCIzindlela zokwelapha ezihlosiwe ziyizidakamizwa eziqondise ama-molecule athile abandakanyeka ekukhuleni kwamangqamuzana omdlavuza kanye nokuphila. Lezi zindlela zokwelapha zisebenza kuphela uma isimila sinokuguquguquka okuthile kofuzo noma ukungajwayelekile kwamaprotheni.Ama-EGFR InhibitorsEGFR (epidermal growth factor receptor) inhibitors asetshenziselwa ukwelapha I-NSCLC ngokuguqulwa kwe-EGFR. Le mithi ivimba amaprotheni e-EGFR, esiza amangqamuzana omdlavuza ukuba akhule. Izibonelo zifaka: I-Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso)ALK InhibitorsALK (anaplastic lymphoma kinase) inhibitors asetshenziselwa ukwelapha I-NSCLC ngokuhlelwa kabusha kofuzo lwe-ALK. Le mithi ivimba iphrotheni ye-ALK, esiza amangqamuzana omdlavuza akhule. Izibonelo zifaka: I-Crizotinib (Xalkori) i-Ceritinib (Zykadia) i-Alectinib (Alecensa) i-Brigatinib (Alunbrig) i-Lorlatinib (Lorbrena)I-ROS1 InhibitorsI-ROS1 inhibitors isetshenziselwa ukwelapha I-NSCLC ngokuhlelwa kabusha kofuzo lwe-ROS1. Le mithi ivimba iphrotheni ye-ROS1, esiza amaseli omdlavuza ukuthi akhule. Izibonelo zifaka: I-Crizotinib (Xalkori) I-Entrectinib (Rozlytrek)I-BRAF Inhibitors I-BRAF inhibitors isetshenziselwa ukwelapha I-NSCLC ngezinguquko ze-BRAF V600E. Le mithi ivimba amaprotheni e-BRAF. Izibonelo zifaka: I-Dabrafenib (Tafinlar) I-Trametinib (i-Mekinist) (isetshenziswe ngokuhlanganiswa ne-Dabrafenib)Ezinye Izindlela Zokwelapha EziqondisiweEzinye izindlela zokwelapha ezihlosiwe zingasetshenziswa kuye ngoshintsho oluthile olukhona esimila. Izibonelo zifaka i-RET inhibitors (ye-RET fusions) kanye ne-MET inhibitors (ye-MET exon 14 skipping mutations).I-Immunotherapy ye-MET Ukwelashwa kwe-NSCLCIzidakamizwa ze-Immunotherapy zisiza amasosha omzimba ukulwa nomdlavuza. Basebenza ngokuvimbela amaprotheni avimbela amasosha omzimba ekuhlaseleni amangqamuzana omdlavuza. Lezi zisetshenziswa kaningi ku I-NSCLC treatment.PD-1/PD-L1 InhibitorsPD-1 (programmed cell death protein 1) kanye ne-PD-L1 (programmed death-ligand 1) inhibitors ivimba indlela ye-PD-1/PD-L1, esiza amangqamuzana omdlavuza ukuba agweme amasosha omzimba. Izibonelo zifaka: I-Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo)CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-associated protein 4) isiza futhi i-CTLA inhibitors ye-immune system ukuthi ivimbe amaseli omdlavuza e-CTLA-4. Isibonelo i-Ipilimumab (Yervoy), evame ukusetshenziswa ngokuhlanganiswa ne-PD-1 inhibitors.Ukuhlanganisa UkwelaphaKuvamile, Ukwelashwa kwe-NSCLC zibandakanya inhlanganisela yezindlela zokwelapha ezihlukene. Isibonelo, ukuhlinzwa kungase kulandelwe yi-chemotherapy noma ukwelapha ngemisebe. Ukwelashwa okuhlosiwe noma i-immunotherapy kungase kuhlanganiswe ne-chemotherapy. Inhlanganisela ethize izoncika esimweni sesiguli ngasinye. Ukuze uthole okwengeziwe ngocwaningo lomdlavuza vakashela I-Shandong Baofa Cancer Research Institute.Isivivinyo SemitholampiloIzinhlolo zezokwelapha ziyizifundo zocwaningo ezihlola izindlela zokwelapha ezintsha noma izinhlanganisela zokwelapha. Iziguli nge I-NSCLC ingase icabangele ukubamba iqhaza ezivivinyweni zokwelashwa ukuze ifinyelele ekwelashweni okuphambili. Ulwazi mayelana nezivivinyo zokwelashwa lungatholakala kusizindalwazi seNational Cancer Institute nakweminye imithombo ehloniphekile.Side Effect ManagementAll Ukwelashwa kwe-NSCLC kungabangela imiphumela emibi. Kubalulekile ukuxoxa ngemiphumela engemihle engaba khona nodokotela wakho futhi ufunde ukuthi ungayilawula kanjani. Ukunakekelwa okusekelayo, njengokulawula izinhlungu kanye nokwesekwa kokudla okunomsoco, kungasiza ukuthuthukisa izinga lempilo ngesikhathi sokwelashwa.I-Prognosis kanye Nokunakekelwa KokulandelelaIsibikezelo se- I-NSCLC kuncike esigabeni somdlavuza, impilo yesiguli iyonke, nokuthi umdlavuza usabela kahle kangakanani ekwelashweni. Ukuqokwa kokulandelela njalo kubalulekile ukuze kuqashwe ukuphindeka futhi kulawule noma yimiphi imiphumela emibi yesikhathi eside yokwelashwa.Ukuzihlangula: Lesi sihloko sinikeza ulwazi olujwayelekile mayelana Ukwelashwa komdlavuza wamaphaphu okungewona omncane (NSCLC). futhi akufanele kubhekwe njengeseluleko sezokwelapha. Hlala uthintana nodokotela wakho noma omunye uchwepheshe wezokunakekelwa kwempilo ukuze uthole izincomo eziqondene nawe mayelana nesimo sakho sezempilo esithile.